

Claire-Anne Siegrist is emeritus Professor of Vaccinology and Pediatrics of the University of Geneva (Switzerland).

After her training and board certification in paediatrics and infectious disease, she obtained an Advanced Immunology Diploma from Aix-Marseille II University (France) and initiated in 1994 a new research group on Vaccinology and Neonatal Immunology, recognized since 1996 as a WHO Collaborating Center. With her thesis on Vaccination in Early Life, she obtained her PD accreditation in 1998. She was nominated as Professor of Vaccinology at the University of Geneva in 1999. She created and directed a chair of Vaccinology at the University of Geneva, was the Director of the Center of Vaccinology of the University Hospitals of Geneva, the Director of the Pediatric Department of the University of Geneva and Head of the WHO Collaborating Center for Vaccine Immunology. She received numerous prizes, including the Bill Marshall Award and the Best Education Prize from the European Society for Paediatric Infectious Diseases.



Professor Siegrist was the President of the Swiss Advisory Committee for Immunizations (CFV/EKIF) between 2004 and 2014. She was nominated as an expert to the UK Joint Committee for Vaccination and Immunization (JCVI) in 2008 and the WHO Strategic Advisory Group of Experts (SAGE) in 2010. She has contributed to a very large number of original scientific publications in the field of vaccine immunology and became known worldwide during her work for the development of a first-in-human Ebola vaccine, and later during the COVID-19 pandemics. The quality and the objectivity of her engagement for the promotion of evidence-based vaccinology is recognized and appreciated worldwide.

Now retired from the University and the Hospital, her main interest has switched from Vaccinology to Neurosciences and she is working full-time as an independent paediatrician to support children, adolescents and young adults using medical hypnosis and associated tools.

She has withdrawn from all her Vaccinology functions, yet apart from Infovac, and has therefore no conflict of interest to report any more.